-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 3, China’s National Food and Drug Administration announced that WuXi Biotech's CAR-T product targeting CD19, Recchio-cel (trade name: Benoda), has been officially approved
Source: State Drug Administration
Ruijio Lun Sai injection (formerly known as: Rui Ji Lun Sai injection) is an anti-CD19 CAR-T product developed by WuXi Juno, which is intended to treat various B cell malignant tumors.
Public information shows that the CAR expressed by the T cells of Ruiji Orenxel injection combined with the extracellular domain of CD19 can cause the intracellular domain of CAR to promote T cell expansion and trigger effector functions to eliminate tumor cells